# Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

> **NCT06313398** · EARLY_PHASE1 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 100 (estimated)

## Conditions studied

- Sickle Cell Disease
- Thalassemia
- Hemoglobinopathy

## Interventions

- **BIOLOGICAL:** Biotin-labeled red blood cells

## Key facts

- **NCT ID:** NCT06313398
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-06-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313398, "Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06313398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*